What Orbital Therapeutics does

Orbital Therapeutics was a privately-held, pre-revenue biotechnology company founded in September 2022 in Cambridge, Massachusetts, that built an integrated RNA medicines platform to develop next-generation RNA-based therapeutics for human disease. The company's core technical approach combined established and emerging RNA technologies (excluding RNAi) with non-viral delivery mechanisms, centered on circular RNA delivered via lipid nanoparticles (LNPs) to enable in vivo cell reprogramming. Its lead preclinical candidate, OTX-201, was an in vivo CD19 CAR-T cell therapy designed to deplete autoreactive B cells and reset the immune system in B cell-driven autoimmune diseases such as rheumatoid arthritis and lupus, aiming to eliminate the costly and complex lab-based manufacturing burden of traditional ex vivo CAR-T therapies.

The business model was that of a preclinical platform biotech: the company did not commercialize products and derived no product revenue, instead pursuing strategic partnerships, licensing, and ultimately acquisition by a major pharmaceutical company. Orbital launched in September 2022 with a founding strategic partnership and license/research collaboration with Beam Therapeutics, gaining shared access to RNA and non-viral delivery technologies spanning vaccines, immunomodulation, protein replacement, and regenerative medicine. It raised a $270 million Series A financing in April 2023 led by ARCH Venture Partners, with participation from Andreessen Horowitz, EXOR, Redmile, and other top-tier biotech investors, and operated with a headcount of 51-100 employees. In October 2025, Bristol Myers Squibb acquired Orbital for $1.5 billion in cash to absorb OTX-201, the RNA platform, and next-generation in vivo CAR-T candidates into BMS's cell therapy portfolio, after which Orbital ceased operating as an independent entity and became a wholly-owned subsidiary of BMS.

Name

Orbital Therapeutics

Legal name

Orbital Therapeutics, Inc.

Website

https://orbitaltx.com

Company type

Private

Founded year

2022

Operating status

Acquired

Headcount range

11–50 employees

Short description

Orbital Therapeutics was a Cambridge, MA-based preclinical biotech founded in 2022 that built a proprietary RNA medicines platform combining circular RNA and lipid nanoparticle delivery to develop in vivo CD19 CAR-T therapies for B cell-driven autoimmune diseases, acquired by Bristol Myers Squibb for $1.5 billion in October 2025.

Ownership category

akta.pro rank

Product category

RNA Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA), RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• RNA therapeutics
• In vivo CAR-T therapy
• Circular RNA platform
• Autoimmune disease therapy
• Lipid nanoparticle delivery

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Pipeline Development and Licensing: Pre-revenue biotech developing RNA-based therapeutics with focus on in vivo CAR-T cell therapies for autoimmune diseases. Revenue derived through strategic partnerships, licensing deals, and ultimately through acquisition by major pharma.

Go-to-market motion1 record

Marketing channels1 record

Core offering

Orbital Therapeutics develops RNA-based medicines, with its lead candidate OTX-201 being a circular RNA in vivo CAR-T therapy intended for B cell-driven autoimmune diseases. The platform combines circRNA construct engineering with lipid nanoparticle delivery to enable in vivo generation of CAR-T cells, eliminating the need for ex vivo cell manufacturing. Additional programs target regenerative medicine and oncology through diverse RNA modalities.

Product overview

Orbital Therapeutics was a single-product biotech company with a proprietary RNA platform. The company's core asset was OTX-201, an in vivo CAR T-cell therapy for autoimmune diseases, combined with its circular RNA delivery platform that enabled reprogramming of cells inside the body. The company was acquired by Bristol Myers Squibb in October 2025 for $1.5 billion.

Differentiator

Problem solved

Functional benefit

Products and services

• OTX-201

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Bristol Myers SquibbcoreStrategic or Co-development Partner · 1 October 2025Bristol Myers Squibb acquired Orbital Therapeutics for $1.5 billion in cash in October 2025. The acquisition provided BMS access to Orbital's lead preclinical candidate OTX-201 (circular RNA therapy for B cell-driven autoimmune diseases), its proprietary RNA platform, and next-generation in vivo CAR-T therapy candidates. The deal enhanced BMS's cell therapy research platform and positioned the company to develop potentially more accessible treatments compared to traditional ex vivo CAR-T therapies.
• Beam TherapeuticscoreStrategic or Co-development Partner · 7 September 2022Orbital Therapeutics entered into a strategic partnership with Beam Therapeutics at launch in September 2022. The license and research collaboration provided shared access to RNA and non-viral delivery technologies for specific applications including vaccines and therapeutic proteins. The partnership focused on leveraging innovative RNA technologies and delivery mechanisms to develop RNA medicines for treating human diseases in areas of vaccines, immunomodulation, protein replacement, and regenerative medicine.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Beam Therapeutics: Beam Therapeutics was Orbital's launch partner and a leading base-editing biotech. Both companies work with RNA and non-viral delivery technologies, and Beam monetized its Orbital stake for $255.1M after the BMS acquisition, making it a directly comparable peer in RNA-based therapeutic development.
• Intellia Therapeutics: Intellia is advancing in vivo CRISPR-based gene editing and cell therapy using LNP delivery for both autoimmune and oncological indications. It is a direct peer to Orbital in the in vivo cell engineering space using non-viral delivery.
• Caribou Biosciences: Caribou develops allogeneic CAR-T cell therapies including allogeneic CAR-T candidates for autoimmune disease. It competes with Orbital in next-generation CAR-T approaches, though focused on ex vivo allogeneic rather than in vivo delivery.
• Arcturus Therapeutics: Arcturus develops RNA-based therapeutics using its STARR and LUNAR delivery platforms, including self-amplifying RNA and conventional mRNA. It is a direct peer in the RNA therapeutics space with non-viral delivery technology comparable to Orbital's circular RNA + LNP platform.
• CRISPR Therapeutics: CRISPR Therapeutics is developing ex vivo and in vivo gene-edited cell therapies, including CAR-T candidates for autoimmune disease. Its work on in vivo gene editing and cell therapy delivery overlaps directly with Orbital's in vivo CAR-T platform.
• Laronde: Laronde is developing endless RNA (eRNA), a circular RNA therapeutic platform. As a direct circular RNA therapeutics competitor with non-viral delivery, it is one of the closest technology peers to Orbital's circular RNA platform.
• Editas Medicine: Editas Medicine develops in vivo and ex vivo gene-editing therapies including cell therapy approaches for cancer and autoimmune disease. It is a comparable peer in the in vivo cell engineering and gene editing therapeutic space.

Broad incumbents

• Moderna: Moderna is the leading mRNA therapeutics company with extensive LNP delivery expertise and a broad pipeline including immuno-oncology and rare disease applications. As an established RNA therapeutics incumbent, it overlaps with Orbital's core technology platform.
• BioNTech: BioNTech is a major mRNA therapeutics company with programs in cancer immunotherapy and infectious disease vaccines. Its work on RNA-based cell therapies and LNP delivery platforms makes it a broad incumbent comparable to Orbital's RNA medicines approach.
• Alnylam Pharmaceuticals: Alnylam is the leading RNAi therapeutics company with established GalNAc and LNP-based delivery platforms. While focused on RNAi rather than mRNA/circular RNA, it is a broad incumbent in the RNA therapeutics space and a relevant comparable.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/orbital-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orbital Therapeutics